MIST — Milestone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $80.70m
- $51.06m
- $1.55m
Brief: FDA Issues Complete Response Letter For Etripamil For PSVT
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray
US FDA declines to approve Milestone's heart rhythm nasal spray (updated)
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
Brief: Milestone Pharmaceuticals enters open market sale agreement with Jefferies
Brief: Milestone Pharmaceuticals Inc Receives Notice Of Allowance On New U.S. Patent For Etripamil
Brief: Milestone Pharmaceuticals Provides 2025 Corporate Outlook And To Host Investor Event On Feb 25 In NYC
Brief: Milestone Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
Milestone Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Stericycle, Oil companies, US Banks
U.S. STOCKS ON THE MOVE-DocuSign, U.S homebuilders, Texas Capital Bancshares
U.S. STOCKS ON THE MOVE-Smartsheet, Bowlero, Samsara
Milestone rises after late-stage data from Chinese partner on heart rhythm drug
Brief: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
Brief: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa To Its Board
Milestone Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Milestone Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Cardamyst™